Case Report ARTICLE
Clinical benefit of pazopanib in a patient with metastatic chondrosarcoma: a case report and review of the literature.
- 1University General Hospital Attikon, Greece
Chondrosarcoma is a rare malignancy characterized by the production of cartilage matrix, displaying heterogeneous histopathology and clinical behavior. Due to lack of effective treatment for advanced disease, the clinical management of metastatic chondrosarcoma is exceptionally challenging. Chondrosardomas harbor molecular abnormalities, such as overexpression of platelet-derived growth factor receptor-alpha (PDGFRA) and PDGFR-beta (PDGFRB), which are required for cancer development, progression and metastasis. Pazopanib is a potent and selective multi-targeted tyrosine kinase inhibitor (TKI), which co-inhibits stem cell growth factor receptor (c-KIT), fibroblast growth factor receptor (FGFR,) PDGFR and vascular endothelial growth factor receptor (VEGFR) and has demonstrated clinical activity in patients with advanced previously treated soft tissue sarcoma (STS). Herein, we describe the unique case of a patient with metastatic chondrosarcoma who derived clinical benefit from pazopanib after first line chemotherapy failure.
Keywords: Pazopanib, metastatic chondrosarcoma, Angiogenesis, VEGFR, PDGFR
Received: 03 Dec 2017;
Accepted: 13 Feb 2018.
Edited by:Anna Rita Migliaccio, Icahn School of Medicine at Mount Sinai, United States
Reviewed by:Antonio Rozzi, Clinical Oncology Unit, Istituto Neurotraumatologico Italiano Grottaferrata (Roma), Italy
Dhiraj Kumar, University of Texas MD Anderson Cancer Center, United States
Copyright: © 2018 Tsavaris, Economopoulou, Kotsantis, Reppas, Avgerinou, Spathas, Prevezanou and Psyrri. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Prof. Amanda Psyrri, University General Hospital Attikon, Athens, Greece, firstname.lastname@example.org